Lv2
130 积分 2024-06-25 加入
Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC — mechanisms and evolving treatment approaches
16天前
已完结
Targeted Inhibition of CYP11A1 in Castration-Resistant Prostate Cancer
2个月前
已完结
Design, synthesis, and biological evaluation of cytochrome P450 CYP11A1 inhibitors
2个月前
已完结
Eleven clinical trials that will shape medicine in 2026
8个月前
已完结
In vivo chimeric antigen receptor (CAR)-T cell therapy
8个月前
已完结
Antibody-Drug Conjugates in Combination Therapy: Defining the Next Chapter
9个月前
已完结
In vivo chimeric antigen receptor (CAR)-T cell therapy
9个月前
已完结
Treatment of NSCLC after chemoimmunotherapy — are we making headway?
10个月前
已完结
Synthetic lethal strategies for the development of cancer therapeutics
10个月前
已完结
Synthetic lethality in cancer drug discovery: challenges and opportunities
10个月前
已完结
皖公网安备34019202002308
